1. France Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Cellectis S.A.

Cellectis S.A.

ALCLS.PA
Cellectis S.A.undefined flagEuronext Paris
2.88
EUR
-0.07
- -
208.15MMarket Cap
Cellectis S.A.
ALCLS.PA
(Euronext Paris)

Recent

price

2.88

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
1.47
0.75
0.36
1.01
1.64
1.27
0.71
0.31
0.36
1.2
0.71
0.42
0.01
0.46
0.73
0.68
Revenue per Share
- -
-2.19
-1.45
-3.7
- -
-0.67
-1.91
-2.78
-1.93
-2.41
-1.91
-2.69
-2.33
-1.77
-0.41
-0.67
-0.67
Basic EPS, GAAP
- -
-1.23
-1.36
-1.3
1.93
-0.02
-1.32
-1.54
-1.79
-1.93
-2.93
-2.9
-1.97
-0.45
0.21
-0.43
-0.41
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
5.19
-1.46
-3.63
-6.11
-4.99
-7.73
-9.83
-9.87
-11.92
-13.75
-16.38
-9.58
-7.04
-3.57
-3.27
-3.45
Book Value per Share
- -
-0.61
1.38
-0.14
2.73
8.41
7.75
7.92
11.01
8.35
7.23
5.53
2.75
1.47
1.43
0.75
0.59
Tangible Book Value per Share
- -
14
20
21
26
34
35
36
41
42
43
42
46
57
91
100
100
Basic Weighted Avg Shares
21
21
15
7
26
56
45
25
13
15
51
30
19
1
42
73
68
Sales/Revenue/Turnover
-73.82
-122.1
-175.13
-494.74
-24.25
-55.46
-150.2
-367.83
-825.47
-813.38
-82.87
-341.01
-467.72
-12,887.81
-143.48
-45.34
-64.73
Operating Margin (%)
2
- -
5
3
2
2
2
3
2
7
8
14
18
19
20
20
20
Depreciation Expense
-11
-31
-29
-77
- -
-23
-67
-99
-79
-102
-81
-114
-106
-101
-37
-68
-67
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-52.98
-149.06
-193.75
-1,033.23
0.09
-40.81
-150.1
-394.51
-618.12
-672.09
-158.79
-376.32
-553.64
-13,385.3
-88.57
-92.66
-98.76
Profit Margin (%)
31
44
25
-4
69
281
256
278
441
329
263
176
81
78
121
90
70
Working Capital
2
68
4
5
3
- -
- -
- -
1
47
100
90
63
71
78
79
78
LT Debt
50
37
71
3
72
288
275
284
450
355
309
236
126
85
131
76
60
Total Equity
- -
- -
- -
- -
-14.61
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
-1.26
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-33.07
Return on Capital (%)
- -
-50.18
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
14
12
9
LT Borrowings
50
51
52
LT Finance Leases
29
28
26
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
100
100
101
Market Capitalization
278
495
329

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
221
236
205
Cash, Cash Equivalents & STI
190
209
186
Accounts Receivable, Net
8
14
5
Inventories
- -
- -
- -
Total Current Liabilities
149
146
134
Payables & Accruals
25
28
24
ST Debt
14
12
9
Deferred Revenue
94
97
93

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-6.72%
-18.06%
-42.07%
Free Cash Flow
510.33%
-119.59%
-324.25%
Net Income, GAAP
28.04%
9.85%
83.87%
Sales/Revenue/Turnover
544.22%
1,059.96%
75.76%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5
8
16
13
42
2025
11
17
35
10
73
2026
6
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
-0.28
-0.23
- -
-0.41
2025
-0.18
- -
0.01
-0.26
-0.67
2026
-0.18
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Dishman Carbogen Amcis Limited (DCAL.BO)
Cassiopea S.p.A. (SKIN.SW)
Landfar Bio-medicine Co., Ltd (000504.SZ)
Kadimastem Ltd (KMSTF)
Marizyme, Inc. (MRZM)
Oncopeptides AB (publ) (ONPPF)
Business
Cellectis SA (Nasdaq:CLLS; Euronext Growth Paris:ALCLS) develops gene-edited allogeneic chimeric antigen receptor (CAR) T-cell immunotherapies using its proprietary TALEN gene-editing technology and PulseAgile electroporation system; the company pioneers off-the-shelf UCART product candidates, including UCART19, UCART22, UCART20x22 and UCART123, targeting hematological malignancies such as B-cell acute lymphoblastic leukemia and acute myeloid leukemia, as well as non-Hodgkin lymphoma and other solid tumors; manufacturing operations support clinical and commercial-scale production of these therapies through facilities producing plasmids, mRNA, viral vectors and GMP-grade UCART cells. Founded in 1999 and headquartered in Paris, France, with additional sites in New York and Raleigh, North Carolina, Cellectis operates primarily in the oncology immunotherapy segment, serving cancer patients through clinical-stage programs and partnerships. The company maintains a robust intellectual property portfolio exceeding 100 patent families and global collaborations with Allogene Therapeutics, Servier, Iovance Biotherapeutics, AstraZeneca and others. In recent developments, Cellectis strengthened its financial position with $264 million in cash as of December 31, 2024, bolstered by a $140 million equity investment from AstraZeneca and full drawdown of a $45.5 million European Investment Bank facility; AstraZeneca's joint research collaboration, initiated in 2023, yielded $47 million in payments by year-end 2024, including milestones for up to 10 novel products in oncology, immunology and rare diseases across three initial programs; both manufacturing sites achieved full operational status in 2022, enabling in-house production advancements.